MRI predictors of clinically definite MS based on analyses of placebo patients from the CHAMPS trial

被引：0
|
作者：
Simon, JH
机构：
来源：
NEUROLOGY | 2002年 / 58卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A502 / A503
页数：2
相关论文
共 50 条
  • [21] Baseline variables predictive of conversion from possible to clinically definite MS: ETOMS results
    Martinelli-Boneschi, F
    Hartung, HP
    Sorensen, PS
    Edan, G
    Fernandez, O
    Durelli, L
    Roveris, M
    Seeldrayers, P
    Barkhof, F
    Filippi, M
    Hommes, O
    Comi, G
    NEUROLOGY, 2002, 58 (07) : A504 - A504
  • [22] Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome suggestive of MS
    Comi, G.
    Filippi, M.
    JOURNAL OF NEUROLOGY, 2008, 255 : 10 - 10
  • [23] Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
    Comi, G.
    Martinelli, V.
    Rodegher, M.
    Moiola, L.
    Bajenaru, O.
    Carra, A.
    Elovaara, I.
    Fazekas, F.
    Hartung, H. P.
    Hillert, J.
    King, J.
    Komoly, S.
    Lubetzki, C.
    Montalban, X.
    Myhr, K. M.
    Ravnborg, M.
    Rieckmann, P.
    Wynn, D.
    Young, C.
    Filippi, M.
    LANCET, 2009, 374 (9700): : 1503 - 1511
  • [24] Increased expression of Tbet in CD4+ T cells from clinically isolated syndrome patients at high risk of conversion to clinically definite MS
    Basdeo, Sharee A.
    Kelly, Siobhan
    O'Connell, Karen
    Tubridy, Niall
    McGuigan, Christopher
    Fletcher, Jean M.
    SPRINGERPLUS, 2016, 5
  • [25] CSF Abnormalities and the Risk of Clinically Definite Multiple Sclerosis in Patients with Clinically Isolated Syndromes: A Meta-Analysis of Placebo Patients from the Interferon Beta and Glatiramer Acetate Clinically Isolated Syndrome Trials
    Riley, Claire
    Smrtka, Jennifer
    Khalid, Shahram
    Wang, Shuang
    Tullman, Mark J.
    NEUROLOGY, 2009, 72 (11) : A78 - A78
  • [26] Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
    Kappos, L.
    Polman, C. H.
    Freedman, M. S.
    Edan, G.
    Hartung, H. P.
    Miller, D. H.
    Montalban, X.
    Barkhof, F.
    Bauer, L.
    Jakobs, P.
    Pohl, C.
    Sandbrink, R.
    NEUROLOGY, 2006, 67 (07) : 1242 - 1249
  • [27] Multiple sclerosis quality of life inventory in patients at risk for clinically definite multiple sclerosis: results from the CHAMPIONS trial
    Miller, D. M.
    Kollman, C.
    Kinkel, R. P.
    MULTIPLE SCLEROSIS, 2006, 12 : S110 - S110
  • [28] Is an altered pattern of cortical activations in patients at presentation with clinically isolated syndromes suggestive of MS influence and subsequent evolution to definite MS?
    Rocca, M
    Falini, A
    Colombo, B
    Ghezzi, A
    Martinelli, V
    Scotti, G
    Comi, G
    Filippi, M
    JOURNAL OF NEUROLOGY, 2004, 251 : 51 - 51
  • [29] Intramuscular interferon beta-1a delays conversion to clinically definite multiple sclerosis in patients with a clinically isolated syndrome: subgroup analyses based on new diagnostic criteria
    Kinkel, R. P.
    O'Connor, P. W.
    Kremenchutzky, M.
    MULTIPLE SCLEROSIS, 2006, 12 : S187 - S188
  • [30] Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes - Reply
    Kappos, L.
    Polman, C. H.
    Freedman, M. S.
    Edan, G.
    Hartung, H. -P.
    Miller, D. H.
    Montalban, X.
    Barkhof, F.
    Bauer, L.
    Pohl, C.
    Sandbrink, R.
    NEUROLOGY, 2007, 68 (14) : 1163 - 1164
12345